The stock rallied 14.8% following earnings, driven by meaningful commercial execution and a strengthening balance sheet that exceeded investor expectations.
- Net product revenues of $25.1 million reflected a resumed growth trajectory for AVMAPKI FAKZYNJA CO-PACK, supported by rising physician confidence and increased prescribing in earlier lines of treatment.
- The company secured up to $75 million in non-dilutive royalty financing with Oberland Capital, drawing $50 million upfront, alongside a $15 million milestone payment, bolstering liquidity without shareholder dilution.
- Encouraging pipeline progress includes completion of enrollment for VS-7375 dose expansion cohorts and FDA fast-track designation for non-small cell lung cancer, with multiple Phase II registration-directed studies underway.
- Commercial efforts focus on new patient starts, earlier treatment adoption, and improving patient adherence to therapy, all showing positive momentum during the quarter.
- Upcoming data updates on the VS-7375 program in October are expected to be an important catalyst for further validation.
Community Discussion